The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1744
Announcement
Download PDF:   US English
Med Lett Drugs Ther. 2025 Dec 22;67(1744):201   doi:10.58347/tml.2025.1744e
Disclosures
Objective(s)

After 53 years of dedicated service, Mark Abramowicz, M.D., President of The Medical Letter, will retire at the end of 2025.

Dr. Abramowicz joined The Medical Letter in 1972 as Editor, carrying forward the mission established by founders Arthur Kallet and Dr. Harold Aaron: to provide independent, unbiased evaluations of new pharmaceuticals and new indications for previously approved drugs.

A pediatrician by training and a journalist at heart, Dr. Abramowicz’s career has always reflected his passion for medicine and clear communication. Before joining The Medical Letter, he trained at Boston City Hospital, served as a Captain in the U.S. Army Medical Corps, and was a full-time member of the Department of Pediatrics at the Albert Einstein College of Medicine.

Over the past decade, Dr. Abramowicz has worked closely with Jean-Marie Pflomm, Pharm.D., Editor-in-Chief, to ensure a smooth transition. Dr. Pflomm will assume the role of President beginning in January 2026, continuing to guide The Medical Letter’s commitment to rigorous, independent medical review.

We extend our heartfelt appreciation to Dr. Abramowicz for his wisdom, guidance, and deep commitment to The Medical Letter for over 50 years.

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article